Abstract Number: 1751 • 2017 ACR/ARHP Annual Meeting
Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Background/Purpose: In the epidemiology of ANCA-associated vasculitis (AAV), an obvious difference between European and Asian populations has been reported. According to the clinical classification, granulomatosis…Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…Abstract Number: 1753 • 2017 ACR/ARHP Annual Meeting
“Recurrent Venous Thromboembolic Events in Granulomatosis with Polyangiitis Patients”
Background/Purpose: The incidence of first-time venous thromboembolic events (VTE) is high in granulomatosis with polyangiitis (GPA). The incidence of recurrent VTE in these patients has…Abstract Number: 1754 • 2017 ACR/ARHP Annual Meeting
Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Background/Purpose: ANCA-associated vasculitides (AAVs) are potentially life-threatening diseases rarely observed in childhood. Whether AAVs in children (cAAVs) differ from adult-onset AAVs (aAAVs) is still not…Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting
Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…Abstract Number: 1756 • 2017 ACR/ARHP Annual Meeting
Interstitial Lung Disease in ANCA Associated Vasculitis: A Distinct or an Incomplete Subset in ANCA Vasculitis Patients?
Background/Purpose: ANCA-associated vasculitis (AAV) are heterogeneous disorders with a clinical presentation that may range from a full-blown disease to incomplete forms with isolated organ involvement.…Abstract Number: 1757 • 2017 ACR/ARHP Annual Meeting
Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients
Background/Purpose: Randomized–controlled trials (RCTs) showed rituximab’s (RTX) noninferiority to cyclophosphamide for induction therapy of severe ANCA-associated vasculitides and significantly lower relapse rate than azathioprine maintenance.…Abstract Number: 1758 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Background/Purpose: Adverse events, rather than active vasculitis, are the greatest threat to patients with ANCA-associated vasculitides (AAVs) during the first year of therapy but long-term…Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…Abstract Number: 1760 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations in Microscopic Polyangiitis and Granulomatosis with Polyangiitis: A Multicenter Cohort Analysis
Background/Purpose: Pulmonary involvement in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) includes pulmonary nodules (PN), diffuse alveolar hemorrhage (DAH), and infiltrates attributed to vasculitis,…Abstract Number: 1761 • 2017 ACR/ARHP Annual Meeting
Differential Characteristics of MPO-ANCA Positive and Negative Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by the preceding history of type I allergic disorders, mostly bronchial asthma, followed by the development of…Abstract Number: 1762 • 2017 ACR/ARHP Annual Meeting
Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Background/Purpose: ETS Proto-oncogene 1, transcription factor (ETS1) is a transcription factor involved in immune responses. Genome-wide association studies on systemic lupus erythematosus (SLE) in Chinese…Abstract Number: 1763 • 2017 ACR/ARHP Annual Meeting
Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry
Background/Purpose: Diagnosing ANCA-associated vasculitides (AAVs) can be challenging. Their clinical presentations are numerous and the time to diagnosis may range from days to years.1,2 The…Abstract Number: 1764 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Background/Purpose: MicroRNAs (miRNAs) are small RNA molecules (~22 nucleotides) that participate in post-transcriptional gene regulation. miRNAs have potential both as biomarkers for diagnosis and prognosis…Abstract Number: 1765 • 2017 ACR/ARHP Annual Meeting
Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis
Background/Purpose: The purpose of this study was to validate the recently proposed ACR EULAR 2017 classification criteria of GPA in a real life cohort of…
